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Abstract
Dioxins and dioxin-like compounds encompass a group of structurally related heterocyclic compounds that bind to and
activate the aryl hydrocarbon receptor (AhR). The prototypical dioxin is 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a highly
toxic industrial byproduct that incites numerous adverse physiological effects. Global commercial production of the
structurally similar polychlorinated biphenyls (PCBs), however, commenced early in the 20
th century and continued for
decades; dioxin-like PCBs therefore contribute significantly to total dioxin-associated toxicity. In this study, PCB 126, the
most potent dioxin-like PCB, was evaluated with respect to its direct effects on hepatic glucose metabolism using primary
mouse hepatocytes. Overnight treatment with PCB 126 reduced hepatic glycogen stores in a dose-dependent manner.
Additionally, PCB 126 suppressed forskolin-stimulated gluconeogenesis from lactate. These effects were independent of
acute toxicity, as PCB 126 did not increase lactate dehydrogenase release nor affect lipid metabolism or total intracellular
ATP. Interestingly, provision of cells with glycerol instead of lactate as the carbon source completely restored hepatic
glucose production, indicating specific impairment in the distal arm of gluconeogenesis. In concordance with this finding,
PCB 126 blunted the forskolin-stimulated increase in phosphoenolpyruvate carboxykinase (PEPCK) mRNA levels without
affecting glucose-6-phosphatase expression. Myricetin, a putative competitive AhR antagonist, reversed the suppression of
PEPCK induction by PCB 126. Furthermore, other dioxin-like PCBs demonstrated similar effects on PEPCK expression in
parallel with their ability to activate AhR. It therefore appears that AhR activation mediates the suppression of PEPCK
expression by dioxin-like PCBs, suggesting a role for these pollutants as disruptors of energy metabolism.
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Introduction
PCBs are a group of bicyclic chlorinated hydrocarbons that are
lipophilic and highly resistant to physical, chemical, and enzymatic
breakdown [1]. PCBs saw widespread industrial use in the United
States from the 1930s until their production was restricted in 1979
under the Toxic Substances Control Act; the Stockholm
Convention on Persistent Organic Pollutants in 2001 banned
PCB production internationally. However, due to seepage into the
environment, accidental spills, and improper disposal, combined
with their persistence and propensity for bioaccumulation, PCBs
are still found at measurable levels in soil [2], fresh water [3],
aquatic wildlife [4], and mammals, including humans [5].
Exposure to PCBs and other dioxins and dioxin-like compounds
incites a variety of adverse neurological, reproductive, develop-
mental, immunological, and metabolic effects in both wildlife and
humans depending on dose, timing, and length of exposure [1].
PCBs comprise two categories: dioxin-like and non-dioxin-like,
depending on their structural and chemical properties as well as
their physiological impact. The term dioxin-like refers to structural
and physiological similarities to the prototypical dioxin TCDD,
a highly toxic byproduct of certain industrial processes. TCDD
and its congeners, including dioxin-like PCBs, are thought to exert
their toxic effects primarily through activation of the aryl
hydrocarbon receptor (AhR), a widely expressed nuclear tran-
scription factor that binds a broad range of xenobiotics [6].
Unliganded AhR resides in the cytosol; binding of a productive
ligand induces translocation into the nucleus, where AhR
dimerizes with the aryl hydrocarbon receptor nuclear translocator,
binds to xenobiotic response elements of its target genes, and
induces transcription. The actual downstream targets of activated
AhR remain largely unknown, but include several members of the
cytochrome P450 (CYP) family of first-phase drug metabolizing
enzymes. The putative mechanism of dioxin-induced toxicity is
a combination of high specificity for AhR binding and persistent
AhR activation secondary to poor metabolism of dioxins by the
CYPs, leading to a range of organ- and species-dependent
maladaptive responses (reviewed in [7]).
Productive AhR binding by a putative ligand is a key requisite
for assignment of a toxic equivalence factor (TEF). The TEF is an
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dioxins and their congeners, and uses TCDD as its reference
standard (TEF=1). The World Health Organization stipulates
that a compound must bear structural similarity to TCDD, bind to
and activate the AhR, and persist and bioaccumulate in the food
chain [1] to be assigned a TEF. PCB 126 is a dioxin-like PCB with
the highest TEF amongst the PCBs (TEF=0.1); the next most
potent PCB congener, PCB 169, has a TEF more than three-fold
lower [8]. Despite its relatively minor contribution as a constituent
of PCB mixtures by weight, the potency of PCB 126 underlies its
toxicological significance as the major contributor to the toxic
equivalent in common PCB mixtures, which may be as high as
90% [9,10]. In humans, a wide range of dioxin-like compounds
can be detected, but the majority of toxicity is attributed to only
seven species, one of which is PCB 126 [5].
The majority of studies pertaining to the metabolic ramifica-
tions of dioxin exposure use animal models, mostly rodents
[11,12,13] — although sensitivity to the wasting effect of dioxins
demonstrates broad strain [11,14] and species [15,16,17] specific-
ity. Coincident observations across such studies include impaired
gluconeogenesis and, more specifically, reductions in the activity,
protein level, and gene expression of PEPCK [14,18,19,20,21].
Given the broader distribution of, and environmental contamina-
tion by, PCBs, compared to TCDD, the effects of PCB 126 on
hepatic glucose metabolism are potentially important. To date,
few studies have characterized the effects of PCB 126 on
mammalian metabolism [21,22] nor the impact of PCB 126 on
hepatic gluconeogenesis in a tightly controlled in vitro system.
While in vivo studies have inherent advantages with respect to
physiological relevance, in vitro systems are arguably optimally
suited for examining the direct effects of PCB 126 in the liver by
avoiding potentially confounding indirect/secondary effects. For
example, enhancement of lipolysis in adipose tissue —secondary,
perhaps, to dioxin-induced anorexia [13]—and the resulting
increase in hepatic FFA delivery could affect HGO in vivo,
whether via substrate-level and/or hormonal mechanisms [23,24].
The present study, therefore, utilizes primary mouse hepatocytes
to address the direct metabolic impact of PCB 126 and the role of
the AhR as a mediator of the effects of dioxin-like PCBs on hepatic
glucose metabolism, with particular emphasis on gluconeogenesis.
Materials and Methods
Ethics Statement
The research presented in this manuscript was conducted using
protocols approved by IACUC at the University of Chicago.
Materials
All PCBs were from AccuStandard (New Haven, CT). Unless
mentioned otherwise, reagents were from Sigma. For a list of PCB
congeners tested, please refer to Table 1.
Isolation and culture of primary mouse hepatocytes
A modification of the non-recirculating two-step perfusion
method as detailed in [25] was used. Eight to twelve week-old male
C57BL/6micewereanesthetizedwithisofluraneandtheportalvein
was cannulated with a twenty-three gauge needle. Upon successful
cannulation, the inferior vena cava (IVC) was immediately cut to
allow fluid to drain. Hank’s Balanced Salt Solution (HBSS;
Invitrogen) containing 5 mM glucose supplemented with 0.5 mM
EGTAand25 mMHEPES(pH 7.4at37uC)wasperfusedat9 mL/
min for 6 min with periodic clamping (5 s clamp every 30 s) of the
IVC to accelerate the process. DMEM containing 5 mM glucose
(Mediatech) supplemented with 100 U/mL Penicillin and 0.1 mg/
mL Streptomycin (Pen/Strep), 15 mM HEPES, and 100 U/mL of
collagenase(TypeIV,Worthington)wasthenperfusedat9 mL/min
foranadditional6to8 mintodigesttheliver.Intermittentclamping
of the IVC was also performed during this step of the process to
augment total cell yield. After sufficient digestion, the gall bladder
was removed and the liver was excised and transferred to a 9.5-cm
Media-Miser dish (Fisher) containing 15 mL of the same medium
usedfordigestion.Cellswereliberatedbytearingandshakingofthe
liver with forceps followed by gentle trituration. The cell suspension
was then filtered through a 74 mm stainless steel strainer (Dual
Manufacturing), washed 3 times by spinning at 506g for 2 minutes
at 4uC, and resuspended inisolation medium (DMEM with25 mM
glucose supplemented with Pen/Strep, 15 mM HEPES, 100 nM
dexamethasone and 10% FBS). Viability and yield were assessed by
counting cells that excluded trypan blue; viability was .90% for all
preparations,withanaverageviableyieldof4610
7cellsperanimal.
Hepatocytes were plated on collagen-coated (5 mg/cm
2 Type I
collagen; BD) 12 or 24-well plates at an initial density of 65–70% to
attain a confluent monolayer the following day. Cells were allowed
toattachfor1 hat37uCinahumidified5%CO2incubator,washed
once with DMEM (5 mM glucose), and the media then changed to
DMEM (5 mM glucose) supplemented with Pen/Strep, 5 mM
HEPES, 10 nM dexamethasone, and 10% FBS. Media was
changed 3 h later to serum-free, phenol red-free DMEM (Media-
tech) supplemented with 5 mM glucose, 44 mM NaHCO3,2m M
L-glutamine, Pen/Strep, 5 mM HEPES (pH 7.4), and 10 nM
dexamethasone for overnight culture/treatment. All cell prepara-
tions were used within 30 h of isolation. Additional details, images,
and videos pertaining to primary hepatocyte isolation and culture
may be found at the primary author’s personal protocol website:
www.mouselivercells.com.
Treatment of cells
Cells were treated at the time and in the media as described
above. For inhibitor studies, cells were pre-incubated as indicated
for 1 h prior to addition of PCBs; all PCB incubations were 16 h
in length unless explicitly noted otherwise. Forskolin stimulation
for gene expression studies was performed for 3 h at a final
concentration of 25 mM after direct addition to cells at h 13. All
compounds and inhibitors were prepared in DMSO; final DMSO
concentration for treatments and vehicle controls were identical
and ranged from 0.35–0.75%.
Total glycogen determination
Glycogen was measured by combination and extensive mod-
ifications of previous methods [26,27]. Following treatment, the
media was removed and cells were washed twice with cold PBS.
Cells were lysed with 0.75% SDS and lysates transferred into
microfuge tubes. A small aliquot was removed for protein
determination (Pierce), and protein was precipitated for 1 h at
4uC from the remainder of the lysate by addition of 100% TCA to
a final concentration of 5–10%. TCA lysates were spun at 4uCa t
14,0006g for 10 min, and 2.5 volumes of 95% EtOH were added
to the supernatant. Glycogen was allowed to precipitate at 280uC
for .1 h, pelleted by spinning at 14,0006g for 20 min at 4uC,
washed with 3 volumes of 70% EtOH, re-spun, and dried using
a SpeedVac. Glycogen was digested using glucoamylase in 0.2 N
sodium acetate (pH 4.4–4.6 at room temperature), and the digest
was neutralized to pH 7.0 with NaOH just prior to glucose
quantification. Liberated glucose was assayed via the glucose
oxidase-peroxidase method by measuring the oxidation of 2,29-
azino-bis(3-ethylbenzthiazoline-6-sulphonic acid; ABTS) at
405 nm (Thermo Multiskan MCC). Conversion of absorbance
to mg glucose was performed against a glucose standard curve.
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Gluconeogenesis was performed in cells after 16 h of treatment.
Briefly, cells were washed twice with glucose-free, phenol red-free
DMEM. The assay was performed in glucose-free, phenol red-free
media supplemented with 44 mM NaHCO3, 2 mM L-glutamine,
Pen/Strep, 10 mM HEPES (pH 7.4), 10 nM dexamethasone, and
10 mM of the specified substrate; 25 mM forskolin was also added
to the appropriate media stocks. At 1 h intervals, an aliquot of
media was removed for analysis of glucose by the glucose oxidase-
peroxidase assay as described for glycogen determination. The
remainder of the media was then removed and fresh media added
for the next time point. At the termination of the assay, cells were
lysed in 0.75% SDS for measurement of protein (BCA).
Lactate dehydrogenase (LDH assay)
LDH in the supernatant was measured using a kit (Cayman
Chemical) with slight modifications to the manufacturer’s instruc-
tions. Total LDH was measured after removal of all media,
washing cells twice with cold PBS, and releasing intracellular LDH
by hypotonic lysis (60 min with shaking at 4uC in the dark in H20
buffered with 5 mM HEPES). Absorbance of the reduced
tetrazolium salt, INT, was measured at 490 nm on a spectropho-
tometer (Molecular Devices Versamax). Conversion of lumines-
cence to LDH activity was performed against an LDH standard.
Ethoxyresorufin-O-deethylase (EROD)
The conversion of 7-ethoxyresorufin (7-ER) to resorufin was
performed by modification of a previous method [28]. Cells were
washed twice in cold PBS, dried quickly by vigorous shaking, and
disrupted by a single round of freezing/thawing (280uC/37uC).
ThawedplateswereplacedoniceandtheERODassaymixturewas
added (1 mg/mL BSA, 5 mM 7-ER, and 0.5 mM NADPH in
50 mMTris(pH 7.4at37uC)).Thereactionwasinitiatedbyplacing
plates on a shaker at 37uC in the dark. Total incubation time was
15 min, and the assay was terminated by addition of 0.8 volumes of
2 M glycine (pH 10.4 at room temperature). The terminated
reactionmixwastransferredintomicrofugetubes,spunfor1 minat
14,0006g at room temperature, and an aliquot of the supernatant
was transferred to a solid black fluorescence microwell plate.
Fluorescenceofresorufinwasassessedonafluorescenceplatereader
(Beckman Coulter DTX 880) at 535 nm excitation/595 nm
emission. Conversion of fluorescence units to ng of resorufin was
performed against a resorufin standard curve.
Quantitative real-time PCR (qRT-PCR)
RNA was isolated using the Qiagen RNeasy kit. Briefly, all
media was removed and cells were rapidly washed twice with cold
PBS. Buffer RLT containing 10 mL/mL b-mercaptoethanol was
added to all wells, and plates were stored immediately at 280uC
for later processing. The purity and concentration of RNA was
assessed using a NanoDrop 2000; 260/230 ratios were consistently
.2.0. Synthesis of cDNA was performed with 0.5 mg of RNA
using the Bio-Rad iScript kit, and was stored at 220uC.
Quantitative RT-PCR was performed using Sybr Green (Bio-
Rad) on a Bio-Rad MyiQ real-time PCR detection system.
Primers (Table S1) were from IDT and were designed using
PerlPrimer v1.1.18; when possible, primer pairs spanned introns.
Primer specificity was assessed by melt curve analysis and agarose
gel evaluation. Gene expression levels were evaluated by the delta-
delta Ct method after confirmation that amplification efficiency
was between 90%–110% for all primer pairs. Ribosomal 18S was
used as a reference gene to control for total mRNA recovery, and
the suitability of 18S as a reference gene was confirmed by
validation against beta-actin expression.
Beta oxidation
Oxidation of palmitate was determined by measurement of
tritiated H20 released during beta oxidation of [9, 10-
3H]-palmitic
acid, based on extensive modification of a previous method [29]. A
concentrated solution of BSA-coupled palmitate was made by
dissolving sodium palmitate in 0.01 N NaOH and adding [9,
10-
3H]-palmitic acid (Perkin-Elmer) in a 70uC water bath. The
labeled mixture was coupled to 2 mM BSA (Jackson ImmunoR-
esearch) in HBSS to reach a final BSA-to-palmitate molar ratio of
3:1. Immediately before addition of the BSA-palmitate concen-
trate, media was removed from wells and replaced with HBSS.
The BSA-palmitate concentrate was then diluted into HBSS
already present in wells to attain the desired palmitate concentra-
tion (200 mM). The reaction was allowed to proceed for 1 h, after
which media was collected, protein precipitated with TCA, and
the clarified supernatant alkalinized with 6 N NaOH; replicate
aliquots of media (specificity standards) that had never been
applied to cells were processed in the same manner to assess
radioactivity not attributable to beta oxidation. Alkalinized
samples were applied to 1 mL columns containing Dowex 162–
400 ion-exchange resin, eluted with water, and the flow-through
counted after addition of scintillation fluid (Beckman Coulter
LS6500); counts from specificity standards were subtracted from
total eluted counts. When used, L-carnitine was added concur-
rently with the substrate, while etomoxir was preincubated for
30 min prior to the start of beta oxidation.
Table 1. Summary of compounds.
Compound CAS Common name Class TEF*
PCB 126 57465-28-8 3,39,3,39,5-pentachlorobiphenyl Non-ortho-substituted coplanar 0.1
PCB 169 32774-16-6 3,39,4,49,5,59-hexachlorobiphenyl Non-ortho-substituted coplanar 0.03
PCB 81 70362-50-4 3,4,49,5-tetrachlorobiphenyl Non-ortho-substituted coplanar 0.0003
PCB 77 32598-13-3 3,39,4,49-tetrachlorobiphenyl Non-ortho-substituted coplanar 0.0001
PCB 105 32598-14-4 2,3,39,4,49-pentachlorobiphenyl Mono-ortho-substituted coplanar 0.00003
PCB 153 35065-27-1 2,29,4,49,5,59-hexachlorobiphenyl Di-ortho-substituted non-coplanar N/A
Myricetin 529-44-2 3,39,4,5,59,7-hexahydroxyflavone Flavonol N/A
*TEF values are based on WHO 2005 published values.
doi:10.1371/journal.pone.0037103.t001
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Lipogenesis from glucose was determined by measuring the
incorporation of [
14C(U)]-glucose (American Radiolabeled Che-
micals) into the lipid extractable fraction of cell lysates. Cells were
incubated with at least 1.5 mCi of
14C glucose per well containing
the indicated concentration of glucose, and the assay was allowed
to proceed for the specified time; if used, insulin was added in
conjunction with radiolabel. The reaction was terminated by
removal of all media followed by three washes with cold PBS. Cells
were hypotonically lysed using H20 (300 mL/well in a 12-well
plate) with gentle rocking at room temperature and then scraped
into 6 mL plastic scintillation vials (PerkinElmer). One additional
volume of H20 was added to wells to facilitate transfer of residual
lysate. Separation of lipid soluble radioactivity was performed by
addition of the maximum volume of organic scintillation fluid
(Betafluor) that still allowed for enough air space to permit shaking
(,4.5 mL). Samples were vigorously shaken and allowed to sit for
.4 h; media
14C standards were processed in the same manner to
ensure specificity of partitioning, and partitioning blanks were
made for
14C standard counting. After partitioning, the organic
phase was carefully transferred to new scintillation vials and
counted (Beckman Coulter LS6500).
14C media standards were
added to partitioning blanks for conversion of counts per minute
into mg of glucose incorporated. Due to the limited ability of even
small volumes of aqueous liquids to remain dispersed in the
organic scintillation fluid, standards were shaken well and counted
immediately in replicate.
Figure 1. Preliminary validation of PCB effects on metabolic functions and toxicity in primary mouse hepatocytes. (A) Suppression of
total intracellular glycogen by increasing doses of PCB 126; *p,0.05 vs. DMSO control. (B) Maximum suppression of total intracellular glycogen at
100 nM PCB 126 after 16 h of incubation; *p,0.05 vs. DMSO control. (C) PCB 126 is not cytotoxic at up to 1 mM, and also does not affect cellular
expression of LDH. (D) PCB 126 has no effect on mitochondrial beta oxidation of palmitic acid; *p,0.05 vs. DMSO for each respective beta oxidation
condition. (E) PCB 126 has no effect on basal or insulin-stimulated lipogenesis; *p,0.05 for insulin effect vs. respective no-insulin control. Unless
otherwise noted, all PCB treatments were 16 h in length. Data are average of 3 experiments; error bars are 2/+ SD.
doi:10.1371/journal.pone.0037103.g001
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ATP was measured using a commercial luminescence kit from
total lysate with slight modifications to the manufacturer’s
instructions (Roche CLS II, #1-699-695). All readings were
performed in 96-well format using a luminescence-capable plate
reader (Beckman Coulter DTX 880). Conversion of luminescence
to ng ATP was performed using an ATP standard curve.
Statistical analysis
Comparisons between two treatments or conditions were
performed with two-tailed Student’s t-tests. Comparisons between
.2 treatments or conditions were made using one-way ANOVA
with post-hoc Tukey-Kramer analysis after confirmation of dataset
normality. SAS JMP 7.0 was used for all analyses, and significance
was set at p,0.05.
Results
PCB126 reduces basal glycogen content in primary
mouse hepatocytes
Previous studies focused on the effect of dioxin-like PCBs on
total glycogen content comprise feeding and/or exposure experi-
ments performed mainly in non-mammalian aquatic animals [30]
and only rarely in mammals [31]. To directly determine the effect
of dioxin-like PCBs on hepatic glycogen levels, primary mouse
hepatocytes were incubated with varying doses of PCB 126 for
16 h; PCB 126 was selected as the reference PCB for this study
due to its TEF (highest amongst PCBs). PCB 126 caused dose-and
time-dependent decreases in glycogen stores, which were maximal
at 100 nM and 12–18 h, respectively; no further reduction was
seen at concentrations up to ten-fold higher or for treatment
periods beyond 18 h (Figure 1A–B). For comparison, PCB 77,
a structurally similar dioxin-like PCB with a TEF several orders of
magnitude lower than that of PCB 126, as well as PCB 153, a non-
dioxin-like PCB with no documented TEF [8], were tested.
Neither PCB 77 nor PCB 153 significantly affected cellular
glycogen levels within the aforementioned concentration and
duration parameters, although PCB 77 trended towards signifi-
cance (p,0.10) (Figure S1).
To confirm that the effect of PCB 126 on glycogen was not
secondary to acute toxicity, lactate dehydrogenase (LDH) release
into the media relative to total intracellular LDH was measured
(Figure 1C). PCB 126 had no effect on total or released LDH at
concentrations up to 1 mM (10-fold higher than the maximally
effective dose of 100 nM). Viability was additionally assessed by
measuring intracellular ATP levels, which were unchanged
(Figure S2). Glycogen levels in cultured primary murine
hepatocytes tend to change inversely with respect to the rate of
beta-oxidation and lipogenesis (unpublished observations), and
others have reported that dioxin-like PCBs and TCDD augment
hepatic lipogenesis [21,32]. However, in the current system, PCB
126 had no effect on beta-oxidation of long-chain fatty acids
(LCFA; palmitate used in this study) under basal conditions
(Figure 1D). Additionally, PCB 126 did not reduce the
stimulation of beta-oxidation by carnitine, which increases
mitochondrial import of LCFAs, nor did PCB 126 affect the
suppression of beta-oxidation by etomoxir, which blocks mito-
chondrial uptake of LCFAs (Figure 1D). PCB 126 also had no
effect on basal or insulin-stimulated lipogenesis from glucose
(Figure 1E), indicating that this agent does not interfere with lipid
metabolism in cultured hepatocytes under the stated conditions.
PCB 126 selectively suppresses forskolin-stimulated
gluconeogenesis from lactate but not glycerol
In the liver, 50% or more of total glycogen arises from the
indirect pathway, where non-glucose precursors provide the
carbon backbone for glycogen via gluconeogenesis (GNG) [33].
Therefore, the impact of PCB 126 on GNG was evaluated by
monitoring the conversion of lactate to glucose. Sixteen hour
pretreatment with PCB 126 did not affect the basal (unstimulated)
rate of GNG. Treatment of cells with the adenylyl cyclase
activator, forskolin, significantly increased GNG in control
hepatocytes, yet this response was markedly reduced by PCB
126 exposure (Figure 2A).
Suppression was evident during the first hour of forskolin
stimulation, and persisted throughout the entire four-hour time
course used for the assay. The contribution of glycogen (due to
glycogenolysis of existing stores) to total glucose output in the
forskolin-stimulated condition was negligible, based on the fact
that 25 mM forskolin induces near-complete glycogenolysis within
30 minutes under the conditions used in these 4 h experiments
(data not shown). Inclusion of 100 nM PCB 126 only during the
4 h GNG assay had no effect on basal or forskolin-stimulated
GNG, indicating that PCB 126 was not exerting its effects via
allosteric inhibition of GNG enzymes (Figure S3). Together,
these results suggested that PCB 126 was suppressing GNG
primarily by blunting forskolin-stimulated gluconeogenic gene
expression. When glycerol was used as a carbon source in place of
lactate, there was an increase in both basal and forskolin-
stimulated GNG (Figure 2B (glycerol) vs. Figure 2A (lactate),
note y-axis units). More interestingly, substitution of lactate with
glycerol as a GNG substrate prevented PCB 126 from suppressing
forskolin-stimulated GNG (Figure 2B). Thus, acute PCB 126
exposure specifically suppresses hepatic GNG in a substrate-
dependent manner, likely at the level of GNG gene transcription.
PCB 126 selectively suppresses forskolin induction of
PEPCK, but not G6pc
GNG is controlled by the expression of several rate-limiting
enzymes, primarily phosphoenolpyruvate carboxykinase (PEPCK)
and glucose-6-phosphatase (G6pc). Several previous studies have
shown that TCDD suppresses the activity and/or expression of
PEPCK [11,12,13,19,20,34], and when measured, the activity of
G6pc decreased more modestly and was subsequent to the effects
of TCDD on PEPCK [13,14,18,19]. To our knowledge, only
a single paper has reported that PCBs decrease PEPCK expression
[21], but the molecular mechanism by which PEPCK mRNA
levels were lowered, and the physiological impact on hepatic
metabolism were not investigated.
To elucidate the mechanism for the suppression of forskolin-
stimulated GNG with lactate but not glycerol, the effect of short-
termforskolinstimulationongluconeogenicgeneexpressioninPCB
126-treated hepatocytes wasevaluated usingqRT-PCR.Consistent
with the GNG data, 16 h PCB 126 treatment did not alter the
expressionofPEPCKmRNAinthebasal(non-forskolinstimulated)
state (Figure 3A, Left). Three hours of 25 mM forskolin treatment
robustly augmented PEPCK transcription in the vehicle-treated
control, while PCB 126 treatment blunted this response by more
than 65% (Figure 3B, Left). In parallel, the regulation of G6pc
geneexpressionbyPCB126intheabsenceandpresenceofforskolin
was determined. Similar to PEPCK, basal levels of G6pc were
unchanged by PCB 126 (Figure 3A, Right). G6pc gene
transcription was also strongly upregulated by forskolin, but unlike
PEPCK, PCB 126 was unable to blunt the induction of G6pc by
forskolin(Figure3B,Right).TheimpactofPCB126andforskolin
PCB126 Inhibits Hepatic Glucose Production
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bisphosphatase(Fbp1),twootherkeyGNGgenes,wasalsoassessed.
Neither gene was significantly induced by 3 h of 25 mM forskolin,
nor did PCB 126 have any effect in the absence or presence of
forskolin (data not shown).
Insulin is the principle means by which PEPCK and G6pc are
hormonally suppressed (reviewed in [35]). To investigate the
specificity of PCB 126 on PEPCK expression, 10 nM insulin was
co-incubated with forskolin, and the induction of PEPCK and
G6pc assessed by qRT-PCR. Insulin did not affect the basal
expression of PEPCK or G6pc (data not shown). However, insulin
suppressed forskolin-driven PEPCK gene expression by approx-
imately 65% (Figure 3C, Left). Unlike PCB 126, insulin potently
suppressed forskolin-stimulated G6pc expression as well
(Figure 3C, Middle). Moreover, the suppressive effect of insulin
was additive to that of PCB 126 with respect to PEPCK
(Figure 3C, Right), resulting in an additional 65% suppression
of PEPCK induction by forskolin. PCB 126 had no effect on other
insulin-responsive metrics (Figure 1E), implying a non-insulin-
related mechanism for PCB 126 specific to suppression of
forskolin-stimulated PEPCK mRNA.
AhR mediates PCB 126 suppression of forskolin-
stimulated PEPCK gene expression
The AhR is the classic target of dioxins, although several studies
have postulated that the effect of TCDD on PEPCK is not
mediated by the AhR [14,18,20]. To evaluate the contribution of
AhR to our findings in primary mouse hepatocytes, the effects of
PCB 126 on gluconeogenic gene expression (PEPCK and G6pc)
and downstream AhR targets was examined. CYP1A1 and
CYP1A2 gene induction, as well as augmentation of EROD
activity, were used as readouts for AhR agonism. Concurrently,
forskolin stimulation of PEPCK and G6Pc gene expression was
compared against PCB 126 concentration. Consistent with AhR
activation, PCB 126 dose-dependently increased transcription of
CYP1A1 (Figure 4A) and CYP1A2 (Figure 4B) and augmented
EROD activity as well (Figure 4C). The three lowest PCB 126
Figure 2. Differential impact of PCB 126 forskolin stimulated hepatic GNG with lactate vs. glycerol. (A) With 10 mM lactate as the
carbon source, PCB 126 (100 nM) has no effect on basal GNG, but suppresses forskolin-stimulated glucose output. (B) With 10 mM glycerol as the
carbon source, PCB 126 has no effect on either basal or forskolin-stimulated GNG, although total GNG is approximately 2-fold higher for all
conditions. *p,0.05 for forskolin effect relative to respective 2/+ PCB condition, #p,0.05 for forskolin effect in DMSO vs. PCB condition. All PCB
treatments were 16 h in length and forskolin (25 mM) was added at the start of the GNG assay as described in Materials and Methods. Data are
average of 3 experiments; error bars are 2/+ SD.
doi:10.1371/journal.pone.0037103.g002
Figure 3. Differential impact of PCB 126 on key forskolin-responsive gluconeogenic genes. (A) PCB 126 has no effect on basal PEPCK or
G6Pc expression. (B) PCB 126 selectively suppresses forskolin induction of PEPCK gene expression, but not that of G6pc. (C) Insulin strongly
suppresses forskolin induction of PEPCK, and the effect of PCB 126 is additive with that of insulin; *p,0.05 for insulin effect within each condition and
gene, #p,0.05 for PCB 126 effect on PEPCK induction independent of insulin. All PCB 126 treatments were 16 h in length while forskolin (25 mM)
and insulin (10 nM) were added at the start of the assay. Data are average of 3 experiments for panels A–B, and 2 experiments for panel C; error bars
are 2/+ SD.
doi:10.1371/journal.pone.0037103.g003
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measurably activate AhR or suppress forskolin-induced PEPCK
expression in a statistically significant manner; however, the next-
highest dose of PCB 126, 5 nM, significantly activated AhR by all
three parameters, and also markedly suppressed forskolin-induced
PEPCK expression (Figures 4A–C). There was no clear relation-
ship between the concentration of PCB 126, AhR activation, and
forskolin-stimulated G6pc expression (Figure 4D), supporting
a specific effect of PCB 126 towards PEPCK. Forskolin-stimulated
G6pc mRNA demonstrated some variance across PCB 126
concentrations tested, but these differences failed to achieve
statistical significance (Figure 4D). Forskolin (25 mM, 3h) had no
measurable effect on CYP1A1, CYP1A2, or EROD by any tested
concentration of PCB 126 (data not shown).
To evaluate, directly, involvement of the AhR in suppression of
PEPCK by PCB 126, AhR inhibitors were screened against 5, 10,
or 20 nM PCB 126; these doses were selected based upon the
observed relationship between AhR activation and PEPCK
suppression (Figure 4A–C). An inhibitor-based approach was
chosen due to the very limited practical (functional) utility of
mature primary hepatocytes in culture, which precluded an RNA
interference approach in this study (see Discussion for more
details). After screening over one dozen compounds shown (in the
literature) to antagonize AhR, only a single flavonol compound,
myricetin, [36], was able to antagonize AhR according to pre-
established screening parameters. That is, at the effective dose, the
compound must (a) not be toxic (Figure S4), (b) antagonize AhR
as assessed by CYP1A1 (Figure 5A), CYP1A2 (Figure 5B), and
EROD (Figure 5C), and (c) have as little intrinsic impact on basal
or forskolin-stimulated PEPCK and G6pc as possible. Although
myricetin significantly suppressed forskolin-stimulated gluconeo-
genic gene expression (Figures 5D and 5E), the effect was
uniform across treatment parameters for both PEPCK and G6pc;
myricetin also possessed the most favorable ratio of AhR
suppression versus impact on PEPCK and G6pc gene induction
amongst the candidate inhibitors. More importantly, myricetin
largely restored forskolin-stimulated PEPCK expression when co-
incubated with maximally effective concentrations of PCB 126 (5–
20 nM; effective defined on the basis of AhR activation), restoring
PEPCK expression to levels seen in the presence of myricetin+-
forskolin alone. In contrast, the effect of PCB 126 exposure on
G6pc expression in the absence and presence of myricetin was
negligible (Figure 5E).
Myricetin was maximally effective at 25 mM, although 10 mM
of myricetin significantly antagonized low (5 nM) concentrations
of PCB 126 (Figure S5). At both 10 mM and 25 mM doses,
myricetin’ s antagonizing power (i.e. the ability of myricetin to
reverse PCB 126 suppression of forskolin-induced PEPCK mRNA
and antagonize PCB 126 induction of AhR) decreased as the ratio
of PCB 126: myricetin increased (Figure S5). Myricetin was not
toxic at the maximally effective dose of 25 mM either indepen-
dently or in conjunction with the highest dose of PCB 126 against
which it was concurrently tested (100 nM PCB 126; Figure S4).
Figure 4. Interaction of CYP1A1, CYP1A2, EROD, and G6Pc versus PEPCK gene expression with PCB 126 dose-response. (A) EC50 of
PCB 126 for CYP1A1gene expression and suppression of forskolin induction of PEPCK gene expression closely correlate. (B) EC50 of PCB 126 for
CYP1A2 gene expression and suppression of forskolin induction of PEPCK gene expression are modestly correlated but demonstrate the expected
directionality. (C) EC50 of PCB 126 for EROD activity induction and suppression of forskolin induction of PEPCK gene expression closely correlate. (D)
Forskolin-induced G6pc gene expression fails to demonstrate a clear relationship with dose-dependent effect of PCB 126 on forskolin-induced PEPCK
gene expression. Tested concentrations of PCB 126 in base 10 format are: 0.05, 0.20 1.0, 5.0, 10.0, 20.0, 100.0, and 500.0. Alphabetical letters separate
doses of PCB 126 that elicited significantly (p,0.05) different degrees of response for the parameter designated on the left-hand y-axis (lowercase) or
right-hand y-axis (uppercase). Data are average of 3 experiments; error bars are 2/+ SD.
doi:10.1371/journal.pone.0037103.g004
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effects as PCB 126 on PEPCK
We subsequently tested the hypothesis that AhR activation by
other dioxin-like PCBs would suppress forskolin-stimulated expres-
sion of PEPCK, but not G6pc, in a manner similar to PCB 126. In
addition to PCB 126, three other non-ortho-substituted coplanar
dioxin-like PCBs were selected for testing: PCB 169, PCB 81, and
PCB 77 (Table 1). PCB 105 was included to represent a mono-
ortho-substituted coplanar dioxin-like PCB with a significantly
lower TEF relative to the other dioxin-like PCBs [8,37]. PCB 153
servedasanegativePCBcontrol,asitisbothnon-coplanarandnon-
dioxin-like, and as such, has no TEF [8]. The PCBs were tested at
fivetimeslowerandhigherdoses(20 nMand500 nM,respectively)
compared to the commonly used dose of PCB 126, 100 nM. The
decision to use higher starting concentrations of PCBs 169, 81, and
77 (i.e. 20 nM instead of 0.05 nM) was based upon the significantly
lower TEFs of these PCBs versus PCB 126. The treatment protocol
was identical to the standard regimen used throughout this paper
(16 h).
AhR activation was assessed by the EROD assay (Figure 6A),
as well as quantification of CYP1A1 (Figure 6B) and CYP1A2
(Figure 6C) gene expression. With the exception of PCB 105, all
of the dioxin-like PCBs were potent activators of the AhR, while,
as expected, PCB 153 was ineffective as an AhR agonist. At the
lowest tested dose for the PCBs (20 nM), only PCB 126 induced
CYP1A activity and gene transcription in a statistically significant
manner (Figures 6A–C). PCB 126 maximally induced CYP1A1
and CYP1A2 at 100 nM, with no further increase at 500 nM; the
other dioxin-like PCBs clustered together with respect to their
potency towards CYP1A1 induction, with statistically significant
dose-dependence, (Figure 6B). At each respective low, middle,
and high dose, PCB 169, PCB 81 and PCB 77 induced CYP1A1
to levels that were not significantly different between compounds
(Figure 6B). Similar trends were observed for CYP1A2
(Figure 6C).
The pattern of EROD activity closely paralleled that of
CYP1A1 gene transcription, with a few notable differences. First,
the greatest overall induction of EROD was observed with
500 nM PCB 81 as opposed to any dose of PCB 126. Also, EROD
activation by PCB 169 was notably weaker than that of the other
dioxin-like PCBs, despite it having the second highest TEF of the
dioxin-like PCBs screened and a relative AhR binding potency
equivalent to that of PCB 81 [37].
The effects of the various PCBs on forskolin-stimulated PEPCK
(Figure 6D) and G6pc (Figure 6E) gene expression were then
evaluated. At the lowest tested dose for this set of experiments
(20 nM), PCB 126 was maximally effective at suppressing
forskolin-induced PEPCK; there was no additional statistically
significant decrease at 100 nM or 500 nM. For all of the other
dioxin-like PCBs, there was a dose-response with respect to PCB
concentration and PEPCK gene suppression. For suppression of
forskolin-induced PEPCK gene expression, there were statistically
significant dose effects both within and between compounds at the
two lower concentrations of each dioxin-like PCB (excluding PCB
Figure 5. Validation and evaluation of myricetin, a putative competitive AhR inhibitor. Doses of PCB 126 were selected based on the
concentrations near the middle (5 nM) or top (10–20 nM) of the respective dose-response curves (established in figure 4). (A) Maximally effective
myricetin doses (25 mM) significantly antagonize PCB 126 –induced CYP1A1 gene expression. (B) Similar effect of 25 mM myricetin on PCB 126
induction of CYP1A2 gene expression. (C) 25 mM myricetin antagonizes EROD activity induction by PCB 126. (D) Myricetin homogeneously suppresses
forskolin-induced PEPCK expression and also restores PEPCK gene induction by forskolin in the presence of PCB 126. (E) Myricetin homogeneously
suppresses forskolin-induced G6pc gene induction by PCB 126, which has no impact on forskolin induction of G6pc expression. (Panels A–C) *p,0.05
for myricetin effect with respective PCB 126 concentration. (Panels D–E) #p,0.05 for myricetin effect within each [PCB 126]. (All panels) Data are
average of 2–3 experiments; error bars are 2/+ SD.
doi:10.1371/journal.pone.0037103.g005
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like PCBs maximally reduced forskolin-stimulated PEPCK
expression, such that there was no significant difference amongst
the dioxin-like PCBs, including PCB 126. Consistent with 100 nM
PCB 126, none of the PCBs, at any concentration, affected
forskolin-stimulated G6pc gene expression (Figure 6E). When the
effect of the various PCBs (at 20, 100, and 500 nM) on magnitude
of CYP1A1 induction was plotted magnitude of suppression of
forskolin-stimulated PEPCK expression, a statistically significant
interaction was observed (Figure S6). When CYP1A2 or EROD
was substituted for CYP1A1, a similar, statistically significant
interaction was seen (data not shown).
Discussion
TCDD, due to its extreme toxicity compared other dioxins and
dioxin-like compounds, is the most widely utilized compound for
dioxin-exposure investigations. Although the TEF of PCB 126 is
an order of magnitude lower than that of TCDD, widespread
production of PCBs for over sixty years implies that the
distribution and concentration of PCB 126, as well as other
dioxin-like PCBs, may be more penetrant than that of TCDD.
One of the few published in vivo metabolic studies using dioxin-
like PCBs reported (Clophen A50, a technical PCB mixture whose
TEF is primarily attributable to PCB 126 [10]), a similar
hypoglycemic effect in PCB-treated rats [21]. However, while in
vivo studies afford insight into whole-body effects, in vitro studies
allow for resolution of direct versus indirect effects. Our findings
support the conclusion that PCB 126 and other non-ortho-
substituted dioxin-like PCB congeners directly suppress hepatic
GNG, an effect mediated through specific suppression of PEPCK
gene transcription by a mechanism that involves the AhR.
Others have reported depression of total hepatic glycogen
following TCDD exposure in rats [9,11] mice [38], fish, [39] and
more recently in embryonic chick liver [34]. However, studies
focused on the effects of PCB 126 on liver glycogen in mammals
are lacking. Furthermore, the majority of studies using TCDD or
PCB mixtures observed decreased glycogen following a several-
day period of treatment [9,11], or used doses that induced
nonspecific toxicity [40]. The fact that short-term treatment with
Figure 6. Other dioxin-like PCBs that activate AhR suppress PEPCK gene induction. (A) Dioxin-like PCBs 126, 169, 81, and 77 induce EROD
activity, with dose-dependency for all dioxin-like PCBs with the exception of PCB 126. (B) Similar trends observed for when CYP1A1 was used as the
readout instead of EROD. (C) CYP1A2 gene expression demonstrates a pattern in line with observations made in panels A and B. (D) Forskolin-induced
PEPCK gene expression is suppressed by other dioxin-like PCBs in a dose-dependent fashion, with the exception of PCB 126. (E) G6pc gene induction
is not affected by any tested PCBs at any tested concentration. *p,0.05 vs. DMSO, significant differences between doses of PCBs are designated by
arrows. Note: for clarity, the PCB prefix has been eliminated for the tested congeners on the x-axis label. Data are average of 2–3 experiments; error
bars are 2/+ SD.
doi:10.1371/journal.pone.0037103.g006
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independent of cytotoxicity—implies that impaired glycogen
metabolism may play an early and primary role in dioxin-induced
hypoglycemia, as opposed to being a secondary, nonspecific
phenomenon. The mechanisms by which PCB 126 suppresses
glycogen remain unclear, as PCB 126 did not affect basal GNG
gene expression or unstimulated rates of glucose production, nor
were changes in the level or phosphorylation state of glycogen
synthase and phosphorylase detected (data not shown). Non-
genomic signaling or allosteric enzyme regulation may each play
a role, given that maximum suppression of glycogen required
concentrations of PCB 126 in excess of the dose needed for
maximal AhR activation. In cell lines, TCDD, through a non-
AhR-mediated mechanism, induces release of intracellular calci-
um [41], which may accelerate glycogenolysis; the lack of effect of
PCB 126 on glycogenolytic rates in our system implies that this is
either not the mechanism, or that experimental conditions may
require modification to specifically interrogate this pathway.
The contribution of GNG to long-term maintenance of
euglycemia during fasting vastly surpasses that of glycogen
(reviewed in [42]). TCDD and PCB 126 suppress both of the
two principal, hormonally regulated gluconeogenic genes, PEPCK
and G6pc, in vivo and in vitro. However, in mammalian studies,
PEPCK suppression occurs earlier and to a greater extent than
G6pc, and demonstrates dose-responsiveness—implying that in
mammalian liver, PEPCK suppression may be specific, and G6pc
suppression a secondary effect.
Both TCDD and a PCB mixture suppress the upregulation of
PEPCK induced by fasting or cAMP analogs [11,21], making the
induced condition (forskolin-stimulated in our study) potentially
more physiologically relevant. Furthermore, we tested lactate and
glycerol as gluconeogenic substrates based on their divergent
points of entry in the gluconeogenic pathway (Figure 7). In
mammals, synthesis of glucose from lactate is under the control of
several critical gluconeogenic enzymes, including Pcx, cytosolic
PEPCK, Fbp1, and G6pc. In contrast, glycerol enters the
gluconeogenic pathway at a more proximal point, and, enzymat-
ically, is subject primarily to regulation by Fbp1 and G6pc [43].
Using these substrates under unstimulated and stimulated
conditions, we found that PCB 126 selectively suppresses
forskolin-stimulated GNG from lactate, but not glycerol. During
gluconeogenesis, pyruvate is regulated in a manner similar to
lactate in the rodent, and we observed similar patterns when
substituting pyruvate for lactate. However, in our hands, pyruvate
(compared to lactate) yields a significantly lower forskolin effect in
the GNG assay, such that statistically significant resolution of PCB
126’s effect is impractical. The underlying reasons for this
discrepancy in vitro are unknown, but may be related to lactate’s
provision of reducing power (NADH), a requirement for sustaining
high (i.e. forskolin-induced) rates of GNG. Our combined
metabolic and molecular findings demonstrate that PCB 126
selectively influences forskolin-stimulated expression of PEPCK.
The absence of effect of PCB 126 on either Pcx or Fbp1 lends
additional support to the specificity of PCB 126 in GNG.
Although previous studies hypothesize an AhR-independent
mechanism for dioxin-mediated PEPCK suppression [20,44],
AhR activation is the prototypical mechanism of action for TCDD
and the dioxin-like PCBs. The current data, in contrast to previous
findings, support direct involvement of the AhR. First, PCB 126
dose-dependently suppressed forskolin-stimulated PEPCK expres-
sion, and the concentration of PCB 126 required for this effect
correlated with the magnitude of AhR activation, demonstrated by
the dose-response curves for CYP1A1 and EROD. Second,
myricetin, an AhR antagonist, largely restored PCB 126-induced
suppression of PEPCK, and this reversal was ablated at doses of
PCB 126 high enough (.20 nM) to overcome the inhibitory effect
of myricetin with respect to the AhR. Third, other non-ortho-
substituted dioxin-like PCBs similarly suppressed forskolin-induced
PEPCK expression in a dose-dependent manner. Finally, a recent
publication reported that in chicken embryo hepatocytes, AhR
mediates TCDD suppression of GNG and gluconeogenic genes,
but through an indirect mechanism involving the TCDD-
inducible PARP (TiPARP) [34]. The findings of this study differ
from ours in that both PEPCK and G6pc were suppressed by
TCDD; differences in the compound used (TCDD vs. PCB 126) as
well as the choice of species/developmental stage of the animal
may account for these differences. For example, in adult avian
species, the mitochondrial isoform comprises up to 90% of total
PEPCK, while in the mouse and rat, the majority of PEPCK is
cytosolic; in humans, the two PEPCK isoforms are roughly equally
distributed (reviewed in [42]).
Gene manipulation and/or more specific, potent AhR inhibi-
tors are potentially useful tools for further elucidation of
mechanism. The former would be ideal, but primary hepatocytes
in standard two-dimensional culture are highly dynamic, and their
phenotype changes rapidly over the course of hours, with
corresponding alterations in gene expression and functional
parameters [45]. Metabolic endpoints in particular rapidly fall
below the limits of reliable detection with available quantitation
methods; variance in absolute substrate output and percent
hormone response increases substantially as well (own observations
and communications).
Weareunawareofexistingpublishedstudiesthatcoupleadiverse
array of functional readouts (hormone-responsive glycogen synthe-
sis, GNG, lipogenesis, and beta-oxidation) with classic molecular
(gene expression) and biochemical (EROD) methods in the field of
toxicology. The relative lack of studies using a direct in vitro
knockdown approach to evaluate similar metabolism-based end-
points in primary hepatocytes perhaps highlights the associated
challenges. Recently, Mao et al. (2011) investigated the effects of
IRE1a knockdown in the liver [46]. The authors transfected
primary hepatocytes in vitro with the IRE1a construct for immuno-
blotting and measured GNG in primary mouse hepatocytes by
a method similar to ours. Notably, the effect of IRE1a siRNA on
GNG (in vitro) was performed in hepatocytes isolated from mice
injected with virus beforehand. Thus, primary hepatocytes are
readily amenable to molecular manipulation post-plating, but
functional in vitro functions may be practical only within a very
short window using existing two-dimensional culture techniques.
Pharmacological AhR antagonists present an alternate or
supplemental strategy for mechanistic AhR investigations in
primary hepatocytes. Unfortunately, there is no widely available
pharmacological inhibitor for the AhR at the moment. Many
studies have reported the ability of plant-derived flavones,
flavonols, and related compounds to inhibit the AhR. Our
inhibitor screen of over one dozen candidates found minimal
efficacy with several relatively well-characterized compounds even
at high micromolar concentrations (i.e. alpha-naphthoflavone,
resveratrol, and quercetin), while other putative inhibitors (i.e.
curcumin and apigenin) had highly variable mouse-to-mouse
efficacy. Almost all tested inhibitors that suppressed AhR
activation by PCB 126 interfered with forskolin-stimulated GNG
gene expression as well. Even myricetin, the most efficacious
candidate, had moderate (but homogeneous) effects on forskolin-
stimulated PEPCK and G6Pc expression. Finally, certain
inhibitors suppressed EROD activity induction by PCB 126 but
augmented CYP1A1 and CYP1A2 gene transcription (i.e. a-
naphthoflavone), or suppressed CYP1A1 and CYP1A2 gene
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seemingly contradictory observations emphasize the importance of
evaluating both EROD and an AhR target gene (or genes) during
inhibitor screens to differentiate between direct effects on EROD
enzymatic activity versus true AhR antagonism.
The mechanism by which productive AhR binding leads to
inhibition of PEPCK gene transcription is currently unclear. The
core AhR response element is present in the region 5 KB
upstream of the mouse cytosolic PEPCK transcription start site,
and Tijet et al. (2005) reported that the mouse PEPCK gene
contains 7 core AhREs in the 25K Bt o+1 KB region [47]. In
their study, a single high-dose TCDD injection in mice (19 h
induction period) resulted in a 4-fold decrease in liver PEPCK
expression in wild-type mice; no impact of TCDD was observed in
AhR-knockout mice. Our findings are in agreement with this and
previous reports, additionally emphasizes the specificity of this
effect towards the gluconeogenic pathway, and most importantly,
bridges existing in vitro molecular and biochemical findings with in
vivo observations by providing functional in vitro data (i.e. GNG).
In-depth mechanistic studies will be required to elucidate the
mechanism by which AhR activation inhibits PEPCK expression.
PCB-mediated inhibition of gluconeogenesis potentially threa-
tens glucose homeostasis and energy metabolism in exposed
humans and wildlife. In apex predators known to bioaccumulate
PCBs (e.g. polar bears), high levels of dioxin-like PCBs may impair
gluconeogenesis during periods of fasting. This could be partic-
ularly dangerous during prolonged periods of food restriction, e.g.
during periods of hibernation or when food availability is
otherwise restricted. In humans, PCB-induced disruptions in
gluconeogenesis may promote hypoglycemia in susceptible
patients during fasting, an effect potentially magnified by
commonly coincident impairments in hepatic function seen in
disease conditions presenting with hypoglycemia (e.g. non-
alcoholic fatty liver disease, hepatitis, alcohol abuse). Impairments
in hepatic glucose mobilization may be particularly important in
individuals taking anti-diabetic medications that predispose the
subject to hypoglycemia (e.g. sulfonylureas, insulin). Even brief
and remote periods of hypoglycemia can lead to lasting
impairments in cognitive function and potentially life threatening
situations. Thus, agents that inhibit escape from hypoglycemia
may pose significant long-term health risks. Given the environ-
mental persistence of dioxin-like PCBs, these chemicals may be
overlooked, underappreciated disruptors of energy metabolism.
In conclusion, this study presents the following novel findings:
(a) PCB 126 directly and rapidly suppresses hepatic glycogen
metabolism; (b) PCB 126 selectively and potently suppresses
forskolin-stimulated, but not basal GNG from lactate, but not
glycerol; (c) PCB 126 selectively, dose-dependently, and directly
suppresses forskolin-stimulated, but not basal PEPCK expression
and has no effect on the other key gluconeogenic genes; (d)
myricetin antagonizes AhR and largely restores forskolin-stimu-
lated PEPCK expression; (e) other dioxin-like PCBs that pro-
ductively bind the AhR mimic the effect of PCB 126 on forskolin-
stimulated PEPCK gene expression. Future investigations using
Figure 7. Simplified visual model of the impact of PCB 126 on hepatic glucose metabolism. Glycolysis, glycogen synthesis, and
gluconeogenesis in a mouse hepatocyte are presented. Forward metabolism of glucose (glycolysis and glycogen synthesis) is depicted by black
arrows, while reverse metabolism of glucose (GNG) is denoted by gray arrows. Enzymes involved in forward glucose metabolism are in standard bold
text, while enzymes involved in reverse glucose metabolism are in italicized bold text. In this model, PCB 126 inhibits GNG from lactate (and pyruvate)
by suppression of PEPCK gene transcription, and also inhibits glycogen by an unknown mechanism. GNG from glycerol is not affected by PCB 126
because glycerol is under the control of Fbp1 and G6pc under conditions that promote GNG, and thus bypasses PEPCK.
doi:10.1371/journal.pone.0037103.g007
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versus readily metabolizable AhR ligands on GNG/PEPCK, and
expanding the database of dioxins and dioxin-like compounds with
respect to their effect on hepatic GNG and gluconeogenic genes
may offer additional mechanistic insight.
Supporting Information
Figure S1 Dioxin-like PCBs suppress glycogen, while
non-dioxin-like PCBs do not. PCB 77 tended to suppress
glycogen, but this did not consistently reach statistical significance
(p,0.10); *p,0.05 vs. DMSO. Data are average of 2–3
experiments; error bars are 2/+ SD.
(EPS)
Figure S2 PCB 126 does not affect total intracellular
ATP content. Total intracellular ATP is not impacted by PCB
126 (100 nM) after incubation in 5 mM or 10 mM glucose-
containing serum-free medium. Data are average of 2 experi-
ments; error bars are 2/+ SD. Note that the effect of glucose on
total intracellular ATP tended towards statistical significance
(p,0.10).
(EPS)
Figure S3 PCB 126 does not allosterically affect GNG
from lactate. Addition of PCB 126 only at the onset of the GNG
assay, and maintaining its presence throughout the standard four-
hour collection period did result in suppression of forskolin-
stimulated GNG from lactate. Note that data are the sum of four
independent samples collected at one-hour intervals; *p,0.05 for
forskolin effect relative to respective 2/+ PCB condition. Data are
average of 2–3 experiments; error bars are 2/+ SD.
(EPS)
Figure S4 Myricetin is not cytotoxic in the presence or
absence of 100 nM PCB 126. At the maximally effective dose
of 25 mM, myricetin does not increase intracellular LDH release
nor impact total LDH activity, independently or in conjunction
with PCB 126 (100 nM). Other final-round candidate inhibitors
are additionally presented for context. Data are average of 2–3
experiments; error bars are 2/+ SD.
(EPS)
Figure S5 Myricetin dose-dependently suppresses AhR
induction, and this effect wanes as [PCB 126] increases.
A complete dose-response curve for PCB 126 is presented,
although myricetin (10 mM and 25 mM) was only tested against
pre-determined concentrations of PCB 126 (0, 5 nM, 10 nM, and
20 nM; 25 mM myricetin was always tested against 100 nM PCB
126 as a negative control for myricetin efficacy. *p,0.05 for
myricetin effect vs. respective no-myricetin PCB condition. Data
are average of 2–3 experiments; error bars are 2/+ SD.
(EPS)
Figure S6 Standard least squares analysis of CYP1A1
activation versus PEPCK induction. PCBs 126, 169, 81, and
77 at 20, 100, and 500 nM were compared with respect to their
activation of CYP1A1 gene expression (x-axis) and inhibition of
PEPCK gene induction (y-axis). Standard least squares linear
regression revealed statistically significant relationship between
magnitude of CYP1A1 induction and PEPCK suppression
(p,0.05). Data are derived from experiments performed for
figure 6. Error bars have been excluded for clarity.
(EPS)
Table S1 qRT-PCR primer sequences and expected
amplicon lengths.
(DOCX)
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